BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 33921102)

  • 1. Knockdown of RRM1 with Adenoviral shRNA Vectors to Inhibit Tumor Cell Viability and Increase Chemotherapeutic Sensitivity to Gemcitabine in Bladder Cancer Cells.
    Zhang X; Taoka R; Liu D; Matsuoka Y; Tohi Y; Kakehi Y; Sugimoto M
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent effect of adenoviral vector expressing short hairpin RNA targeting ribonucleotide reductase large subunit M1 on cell viability and chemotherapeutic sensitivity to gemcitabine in non-small cell lung cancer cells.
    Tokunaga Y; Liu D; Nakano J; Zhang X; Nii K; Go T; Huang CL; Yokomise H
    Eur J Cancer; 2015 Nov; 51(16):2480-9. PubMed ID: 26254808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Potent Chemotherapeutic Strategy with Eg5 Inhibitor against Gemcitabine Resistant Bladder Cancer.
    Sun L; Lu J; Niu Z; Ding K; Bi D; Liu S; Li J; Wu F; Zhang H; Zhao Z; Ding S
    PLoS One; 2015; 10(12):e0144484. PubMed ID: 26658059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ribonucleotide reductase subunit M1 is a possible chemoresistance marker to gemcitabine in biliary tract carcinoma.
    Ohtaka K; Kohya N; Sato K; Kitajima Y; Ide T; Mitsuno M; Miyazaki K
    Oncol Rep; 2008 Aug; 20(2):279-86. PubMed ID: 18636187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Relationship between the level of RRM1 expression and the sensitivity to gemcitabine in the esophageal squamous cell carcinoma cell lines].
    Luo Y; Lin C; Zhang XY; Liang X; Fu M; Feng FY
    Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):660-3. PubMed ID: 20021860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1).
    Vena F; Li Causi E; Rodriguez-Justo M; Goodstal S; Hagemann T; Hartley JA; Hochhauser D
    Clin Cancer Res; 2015 Dec; 21(24):5563-77. PubMed ID: 26228206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A kinome screen identifies checkpoint kinase 1 (CHK1) as a sensitizer for RRM1-dependent gemcitabine efficacy.
    Zhou J; Chen Z; Malysa A; Li X; Oliveira P; Zhang Y; Bepler G
    PLoS One; 2013; 8(3):e58091. PubMed ID: 23483975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of chemoresistance-related mRNAs based on gemcitabine-resistant pancreatic cancer cell lines.
    Zhou J; Zhang L; Zheng H; Ge W; Huang Y; Yan Y; Zhou X; Zhu W; Kong Y; Ding Y; Wang W
    Cancer Med; 2020 Feb; 9(3):1115-1130. PubMed ID: 31823522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Silencing of ribonucleotide reductase subunit M1 potentiates the antitumor activity of gemcitabine in resistant cancer cells.
    Wonganan P; Chung WG; Zhu S; Kiguchi K; Digiovanni J; Cui Z
    Cancer Biol Ther; 2012 Aug; 13(10):908-14. PubMed ID: 22785206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long noncoding RNA NORAD acts as a ceRNA mediates gemcitabine resistance in bladder cancer by sponging miR-155-5p to regulate WEE1 expression.
    Yang Y; Zhang G; Li J; Gong R; Wang Y; Qin Y; Ping Q; Hu L
    Pathol Res Pract; 2021 Dec; 228():153676. PubMed ID: 34753061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytoplasmic RRM1 activation as an acute response to gemcitabine treatment is involved in drug resistance of pancreatic cancer cells.
    Kato T; Ono H; Fujii M; Akahoshi K; Ogura T; Ogawa K; Ban D; Kudo A; Tanaka S; Tanabe M
    PLoS One; 2021; 16(6):e0252917. PubMed ID: 34111175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Expression of Gemcitabine-resistance-related gene and polymorphism of ribonucleotide reductase M1 gene promoter in Gemcitabine-resistant A549/Gem and NCI-H460/Gem cell lines].
    Liu XQ; Wang WX; Lin L; Song ST
    Zhonghua Zhong Liu Za Zhi; 2010 Jan; 32(1):17-21. PubMed ID: 20211060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sclareolide enhances gemcitabine‑induced cell death through mediating the NICD and Gli1 pathways in gemcitabine‑resistant human pancreatic cancer.
    Chen S; Wang Y; Zhang WL; Dong MS; Zhang JH
    Mol Med Rep; 2017 Apr; 15(4):1461-1470. PubMed ID: 28259943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MiR-608 regulating the expression of ribonucleotide reductase M1 and cytidine deaminase is repressed through induced gemcitabine chemoresistance in pancreatic cancer cells.
    Rajabpour A; Afgar A; Mahmoodzadeh H; Radfar JE; Rajaei F; Teimoori-Toolabi L
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):765-775. PubMed ID: 28887583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long non-coding RNA GHET1 contributes to chemotherapeutic resistance to Gemcitabine in bladder cancer.
    Li B; Xie D; Zhang H
    Cancer Chemother Pharmacol; 2019 Jul; 84(1):187-194. PubMed ID: 31115606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer.
    Nakahira S; Nakamori S; Tsujie M; Takahashi Y; Okami J; Yoshioka S; Yamasaki M; Marubashi S; Takemasa I; Miyamoto A; Takeda Y; Nagano H; Dono K; Umeshita K; Sakon M; Monden M
    Int J Cancer; 2007 Mar; 120(6):1355-63. PubMed ID: 17131328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased antitumor capability of fiber-modified adenoviral vector armed with TRAIL against bladder cancers.
    Zhao Y; Li Y; Wang Q; Wang L; Yang H; Li M
    Mol Cell Biochem; 2011 Jul; 353(1-2):93-9. PubMed ID: 21437625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long noncoding RNA FOXD2-AS1 accelerates the gemcitabine-resistance of bladder cancer by sponging miR-143.
    An Q; Zhou L; Xu N
    Biomed Pharmacother; 2018 Jul; 103():415-420. PubMed ID: 29674277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MiR-9-3p regulates the biological functions and drug resistance of gemcitabine-treated breast cancer cells and affects tumor growth through targeting MTDH.
    Wang Y; Dong L; Wan F; Chen F; Liu D; Chen D; Long J
    Cell Death Dis; 2021 Sep; 12(10):861. PubMed ID: 34552061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. STIM1 Mediates Calcium-Dependent Epigenetic Reprogramming in Pancreatic Cancer.
    Kutschat AP; Hamdan FH; Wang X; Wixom AQ; Najafova Z; Gibhardt CS; Kopp W; Gaedcke J; Ströbel P; Ellenrieder V; Bogeski I; Hessmann E; Johnsen SA
    Cancer Res; 2021 Jun; 81(11):2943-2955. PubMed ID: 33436389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.